Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab

Cheng Yi Loo ; Elwes, Flora ; et al.

In: BMC Ophthalmology, Jg. 18 (2018), Heft 1, S. 1-8

Online unknown

Zugriff:

Background To assess the effect of switching patients previously incompletely treated with ranibizumab (RBZ) to aflibercept (AFL) using a pro re nata (PRN) treatment strategy in neovascular age-related macular degeneration (nvAMD). Methods A retrospective case series was conducted on patients who had persistent or recurrent intra- and/or sub-retinal fluid treated initially with RBZ and subsequently switched to AFL. The main outcome measures were best corrected visual acuity (BCVA) and central retinal thickness (CRT) measured at different stages of the study. Friedman analysis of variance and Wilcoxon test were used to examine differences in BCVA and CRT. Results Two hundred and seven eyes from 182 patients were included. BCVA and CRT improved significantly initially following 3 RBZ injections with a mean gain of 3.7 letters (p

Titel:	Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
Autor/in / Beteiligte Person:	Cheng Yi Loo ; Elwes, Flora ; A M Armbrecht ; Cackett, Peter ; Borooah, Shyamanga ; Aspinall, Peter ; Dhillon, Baljean ; Peng Yong Sim
Link:	View record in OpenAIRE (Volltext) https://doi.org/10.1186/s12886-018-0688-3
Zeitschrift:	BMC Ophthalmology, Jg. 18 (2018), Heft 1, S. 1-8
Veröffentlichung:	Springer Science and Business Media LLC, 2018
Medientyp:	unknown
ISSN:	1471-2415 (print)
DOI:	10.1186/s12886-018-0688-3
Schlagwort:	Male medicine.medical_specialty Time Factors Visual acuity genetic structures Recombinant Fusion Proteins Visual Acuity Angiogenesis Inhibitors 03 medical and health sciences 0302 clinical medicine Clinical Protocols lcsh:Ophthalmology Pro re nata Ranibizumab Ophthalmology Journal Article medicine Humans In patient 030212 general & internal medicine Dosing Retrospective Studies Aflibercept Aged, 80 and over Drug Substitution business.industry Treatment regimen Age-related macular degeneration Anti-VEGF General Medicine Macular degeneration medicine.disease Receptors, Vascular Endothelial Growth Factor Treatment Outcome lcsh:RE1-994 Intravitreal Injections Wet Macular Degeneration 030221 ophthalmology & optometry Female medicine.symptom business Tomography, Optical Coherence Research Article Follow-Up Studies medicine.drug
Sonstiges:	Nachgewiesen in: OpenAIRE File Description: application/pdf Rights: OPEN

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.